Topic: rheumatoid arthritis
Even as AbbVie’s industry-leading Humira faces its eventual sales decline, the company can be thankful that it has two out of the three top launches of 2019, based on 2024 sales.
Pfizer’s Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s high-dose hopes in RA. Could new data help the cause?
Eli Lilly and Incyte’s Olumiant path has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Can new safety data help?
AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
Pfizer said earlier this month that it would change its dosing in a Xeljanz trial after higher doses raised safety flags.
Pfizer has run into safety issues with Xeljanz. But whether the issues belong to the drug—rather than to its burgeoning class—remains to be seen.
Pfizer moved rheumatoid arthritis patients to a lower Xeljanz dose after a data monitoring board highlighted safety concerns for the 10-mg arm.
Humira was only a couple million dollars away from its $20 billion sales goal for 2018, but 2019 will be worse, say AbbVie executives.